|
DANR, MOTR, ENMD, SAVW, SMKG, UNVC
Our Stocks to Watch tomorrow include Dana Resources Inc. (OTCBB: DANR), Motricity Inc. (NASDAQ: MOTR), EntreMed Inc. (NASDAQ: ENMD), SavWatt USA Inc. (OTCBB: SAVW), SmartCard Marketing Systems Inc. (OTC: SMKG) and Univec Inc. (OTC: UNVC).
DANA RESOURCES INCORPORATED (OTCBB: DANR)
"Up 200.00% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/DANR.php
Dana Resources is a precious and base metals exploration company with offices in the United States and Peru. Dana’s management team possesses local knowledge, extensive international connections, a wealth of experience and technical expertise in mining, mining finance, exploration and production. Dana Resources has acquired a portfolio of gold, silver and other precious & base metal properties located in Peru’s most prolific mining regions. With Peru growing as a producer of gold, silver and other metals on the international market, Dana Resources is well positioned to capitalize on the escalating global demand for commodities. The management team and Directors are committed to creating value for their shareholders and to the long-term success of Dana Resources.
DANR News:
January 27 - Investment Report On Dana Resources Inc.
A Reuters Investment Profile has been released on Dana Resources Inc. (OTCBB: DANR). According to Reuters, “This report is essential reading for any serious investor, providing comprehensive financial information on a company's performance, position and cash flows over the past 3 years, including interim data.” To view the report, visit http://bit.ly/wtjDyx.
MOTRICITY INCORPORATED (NASDAQ: MOTR)
"Up 33.33% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/MOTR.php
Motricity empowers mobile operators, brands and advertising agencies to maximize the reach and economic potential of the mobile ecosystem through the delivery of relevance-driven merchandising, marketing and advertising solutions. Motricity leverages advanced predictive analytics capabilities to deliver the right content, to the right person at the right time. Motricity provides their entire suite of mobile data service solutions through one, integrated, highly scalable managed service platform. Motricity's unique combination of technology, expertise and go-to-market approach delivers return-on-investment for our mobile operator, brand and advertising agency customers.
MOTR News:
February 1 - Motricity Appoints James L. Nelson as Chairman of the Board
Motricity (NASDAQ: MOTR) announced that its Board of Directors has named current director James L. Nelson as the company's Chairman of the Board effective January 13, 2012. Mr. Nelson assumes the position from Lady Barbara Judge who remains on the board.
Over the course of his career, Mr. Nelson has provided executive leadership across several industries including financial services, gaming, energy and entertainment. From 1986 to 2009, Mr. Nelson served as Chairman and Chief Executive Officer of Eaglescliff Corporation, a specialty investment banking, consulting and wealth management company. In addition, Mr. Nelson was Chief Executive Officer and Co-Chairman of Orbit Aviation, Inc., from 1998 to 2003, where he engaged in the acquisition and completion of Boeing Business Jets for private and corporate clients.
"As a tested leader with proven management expertise, I'm confident that Mr. Nelson is an ideal choice to lead our Board of Directors," said Jim Smith, interim chief executive officer of Motricity. "I think Motricity stands to benefit from Mr. Nelson's extensive background in corporate development and operations as well as his deep industry knowledge in areas that are strategic to our growth as a company."
Currently, Mr. Nelson serves as a director and member of the audit committee for several companies including Take-Two Interactive Software, Inc., a global publisher and developer of interactive entertainment software products, Icahn Enterprises GP, American Entertainment Properties Corporation, Cequel Communications, an owner and operator of a large cable television system and Tropicana Entertainment Inc.
ENTREMED INCORPORATED (NASDAQ: ENMD)
"Up 20.50% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/ENMD.php
EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.
ENMD News:
January 23 - EntreMed Secures $10 Million Strategic Financing
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has secured $10 million in financing with strategic accredited investors, including IDG-Accel China Growth Fund II L.P. ("IDG"), Emerging Technology Partners, LLC ("ETP"), and Dr. Tak W. Mak, Director of The Campbell Family Institute for Cancer Research.
The Company entered into purchase agreements with the investors, pursuant to which the Company has agreed to issue and sell to the investors convertible notes in the aggregate principal amount of $10 million. The investors also will be issued warrants covering a number of shares of common stock equal to 20% of the principal amount of the notes, divided by $1.15. The warrants are exercisable at $1.40 per share. The closing of the transaction is anticipated to occur on or about January 27, 2012 upon the satisfaction of certain conditions.
At the closing, IDG and ETP have the right to designate in the aggregate two members of the Company's Board of Directors. In addition, it is expected that the Company will select an interim Chief Executive Officer.
Subject to the approval of the Company's stockholders at the 2012 stockholder meeting, the notes will automatically and immediately convert into shares of common stock and the warrants will become exercisable. The notes have a maturity date of August 31, 2012, bear an interest rate of 6% and will convert at a conversion price of $1.15 per share. The conversion price reflects the 10-day average closing sale price ending on January 20, 2012. The notes are not convertible, and the warrants are not exercisable, prior to receiving stockholder approval. If stockholder approval is not obtained, the Company will be required to pay liquidated damages to the note purchasers equal to an aggregate of $1.2 million.
"We are very pleased to have the support from a group of knowledgeable investors and the validation of the potential of ENMD-2076. The proceeds from the notes will allow the Company to accelerate and expand its research and development activities, fund additional trials, initiatives and long term strategic plans," said Michael M. Tarnow, the Company's Executive Chairman.
After deducting transaction fees and expenses, the net proceeds to the Company will be approximately $9.3 million. The convertible notes, the warrants and the common stock into which the notes and warrants are convertible have not been registered under the Securities Act of 1933, as amended (the "Act") and applicable state securities laws, but have been offered and sold in the United States pursuant to applicable exemptions from registration requirements under the Act and applicable state securities laws. This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state.
ABOUT ENMD-2076
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma. ENMD-2076 is currently in a Phase 2 trial for ovarian cancer, and preclinical and clinical activities are ongoing in assessing the compound's applicability for other forms of cancer.
SAVWATT USA INCORPORATED (OTCBB: SAVW)
"Up 100.00% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/SAVW.php
Fast becoming the market leader in LED lighting, SavWatt focuses on developing innovative, energy-efficient and cost-effective LED lighting solutions. By delivering value added, application-specific LED lighting systems, we can significantly reduce energy costs and minimize our carbon footprint world-wide. SavWatt is leading the LED lighting revolution and setting the stage to obsolete the incandescent light bulb. SavWatt's product families include LED fixtures, bulbs, street lights, and parking lights.
SAVW News:
January 5 - SavWatt CEO's New Year Message to Shareholders
SavWatt USA, Inc. (OTCBB: SAVW), pioneers in LED lighting and the Green Revolution, released a New Year message from SavWatt's CEO, Mr Ike H. Sutton.
Dear Shareholders,
We are now at a pivotal point in SavWatt's history; 2011 has closed with a long list of accomplishments and we are starting 2012 with a long list of goals. Building a new business takes focus, determination, and support from all those involved. We are slowly becoming a major force in the new LED revolution, a supplier of a product which is a game changer for an industry that has been around for 100 years, and an innovator of new technology for energy saving and green initiatives.
Our 2011 accomplishments are attributed to the efforts of SavWatt's team which is now 30 and growing. I would like to highlight a few:
* We have completed Phase 1 of the Baltimore facility build-out; our LED Quality Control Burn in Machine has been installed and tested. LED Bulbs are put through a 6 hour testing regimen before being shipped to clients providing the highest level of quality control in the industry and enabling SavWatt to offer a 4 year warranty. Additionally, 2 assembly lines have been installed to produce orders that require Built in America status which will make available US government stimulus funds.
* Company sales offices in New York, Florida, Virginia, and soon to open in California have been established and staffed. Our focus has been areas with high cost of energy — note each of these areas the cost of energy exceeds .15 per kilowatt, which makes LED bulb replacement a must.
* International subsidiaries have been established in Asia and Europe in anticipation of global distribution of SavWatt products.
* An Exclusive Worldwide License has been entered into with P2i, a provider of a patented nano coating which will make our LED bulbs water and dirt resistant, a major differentiator from suppliers like Phillips, GE and Sylvania.
* Our Ecopoles have been installed in strategic locations for testing and continued to be installed and upgraded. These tests provide valuable information for deployment of thousand units worldwide in the upcoming years. The ecopole has been classified as art sculpture and is aesthetically acceptable by communities nationwide.
* Savwatt's web site, a project by itself. The site tracks all our products, specifications and uses. It tracks our ecopoles location with pictures, provides a calculator for all to see the saving affect of our LED lights, and is a repository of all news and sec information for our investors.
* Our products are constantly changing due to technology advancements in this area. We pride ourselves as being able to bring the latest technological engineered products to market before our competitors due to our size and determination. Our products consist of outdoor, indoor, and our totally off the grid ecopoles and soon to be released sunpoles.
* Our suppliers overseas and in the USA have recognized that our vision and marketing efforts are unique and have either entered into exclusive distribution agreements or partnership agreements to make SavWatt the brand of choice worldwide.
* We have attended several trade shows over the year and have developed a database of hundreds of Energy Solution Providers that are hungry for information and partnership; we look forward to developing these relationships.
* We have retained 3rd party consultants to apply for Carbon Credits for our ecopoles. With a projection of 10,000 units a $15 million carbon credit plan is in the works. Coupled with a successful forward sale of these credits, these funds will provide SavWatt substantial working capital for their deployment worldwide.
* Our shareholder based grown to over 3,000 shareholders and this is one of our major assets for the new year.
We, like any other business, had a few disappointments and we are dealing with them. Our relationship with Humanim was terminated as our vision and their boards vision parted ways. DTC which clears stock for all brokerage houses decided not to clear our stock electronically, creating hardship for shareholders to buy and sell our shares, but on a good note, it also limits the shorting of the stock. We are trying to rectify this matter but it is out of our control and is affecting all small micro cap stocks. Our quarterly filings in 2011 were late and we have taken actions to make sure that all our required SEC filing are made on time.
For 2012 we have many resolutions and goals, but to name the top 3:
* Share Valuation - we would like to see a major increase in valuation. Our industry values companies at a minimum of 4 times revenues. Our minimum sales goal for 2012 is $10 million. We have planted the seeds and in 2012 we should start to see the results of our efforts.
* Higher Exchange - we would like to move to Amex or Small Cap Nasdaq -- we are currently evaluating their requirements and creating a plan that will enable to achieve this goal.
* Cash Flow Positive - we believe that by mid-year we will be cash flow positive. Our projection, cash requirements, sales objectives are being monitored daily in order to achieve these goals.
In regards to funding and dilution, a touchy subject, which I receive many emails and calls daily, I would like to point out and remind all shareholders that SavWatt is a Development Stage company. We have accomplished a lot in 2011 but still are pre-substantial revenues; we are still not cash flow positive. We are raising funds through short term convertible loans; these loans when converted do dilute the stock. This method of financing is necessary to grow our business; we are not bankable and do not have a major company big brother. In fact all the shareholders should consider themselves venture capitalists. The alternative and easier solution to this is to accept a $10 million funding from a venture capital firm, give up control and 80% ownership and be subject to a share reverse and major dilution. I believe the road we have taken is best for all shareholders including myself. It provides the cash needed for operations and growth. Based on current share price and 3.1 billion shares outstanding as of today, our company has a valuation of under $1 million, as stated above our goal for 2012 is for a much higher valuation. As venture capitalists, building a business takes time and is not for day traders.
For this new year, I would like to thank the support of our shareholders which is our major asset. We have grown and developed due to their support. I have only one request for the new year that is in regards to SavWatt's bashers on online chat boards. Ask yourself why are they bashing SavWatt? If they are shareholders, why bash? This only creates negativity in the marketplace. If they are not shareholders, why are they on the board? Are they being paid for bashing? By whom and what's the purpose? And if they are really unhappy with SavWatt and the SavWatt team, get out of the stock and move on. Please do not listen or act based on basher information as they have an agenda of their own and provide misinformation to the determent of the company.
On a positive note, we are providing a product that saves energy, is green and is mandated by government regulations. The opportunity is huge; we are aggressively working our plan and we will succeed.
Happy and Healthy New Year and Regards to All.
Ike H. Sutton, CEO
SavWatt USA, Inc.
SMART CARD MARKETING SYSTEMS (OTC: SMKG)
"Up 280.95% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/SMKG.php
Smart Card Marketing Systems, Inc. was established in 2003 and is a leading provider of prepaid cards, value smart storage cards and payment processing services. The company’s current as well as long-term goal is enticing national and international organizations with millions of potential customers and vendors, to purchase and market Smart Card’s products. Smart Card plans to achieve this goal by offering a powerful sales organization and merchant reseller marketing program utilizing their GoSmartCard platform. All of Smart Card’s products and services were developed and designed for international markets, and the company will selectively market to new countries and territories with a prudent and financially beneficial plan using existing, proven and experienced strategic alliances.
UNIVEC INCORPORATED (OTC: UNVC)
"Up 50.00% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/UNVC.php
Univec, Inc., through its subsidiaries, produces, licenses, and markets medical products in the United States and internationally. It primarily provides auto-disable and safety syringes. The company offers 1 cc AD-syringe for aspirating and non-aspirating applications, which are used for dispensing dosages of allergy, immunization, and insulin medicines. It also manufactures and markets sliding sheath syringes that are designed to protect patients and healthcare workers from needle stick injuries; and bifurcated needle safety syringes, which are used in administering smallpox vaccines in response to bio-terrorist threats. Univec markets its auto-disable syringes and sliding sheath safety syringes to private hospitals, health facilities, and distributors in the United States, as well as to governments of developing countries. In addition, it assists pharmaceutical companies in marketing, fulfillment, and tracking drug samples via an online system connecting pharmacies and managed payment providers. The company was founded in 1992 and is based in Baltimore, Maryland.
UNVC News:
January 27 - Investment Report On Univec Inc.
A Reuters Investment Profile has been released on Univec Inc. (OTC: UNVC). According to Reuters, “This report is essential reading for any serious investor, providing comprehensive financial information on a company's performance, position and cash flows over the past 3 years, including interim data.” To view the report, visit http://bit.ly/zPue7X.
|
